12th Annual Forum on Pharma & Biotech Patent Litigation Returns to Amsterdam February, 2020

Be part of the only event where the “Who’s Who” of the European Life Sciences Patent Bar gather each year to shape patent litigation policies and procedures.

Important subject matters to discuss presented by renowned specialists. An important conference to attend.”

— M. Rocha, ABREU ADVOGADOS

C5’s Pharma and Biotech Patent Litigation conference, taking place on 25-26 February 2020 in Amsterdam, is the largest annual gathering of leading in-house IP counsel, patent prosecutors and litigators, judges, and IP policy experts from around the globe.

Attend this event and come away with the knowledge and skills you need to address post-filing patent litigation challenges, and optimise your patent litigation strategy to continuously deliver efficient patent protection in a competitive marketplace.

See what’s new for 2020:

  • Judicial Insights from Dr. Massimo Scuffi, Former Supreme Court Judge, Rome, Member of Italian Patent & Trademarks Board of Appeals, President Emeritus of Intellectual Property Judges Association
  • Brand new faculty members from: Sandoz International, Zentiva, Die Grünenthal Gruppe, Merck, Novartis, Biotest AG, Valneva, Confo Therapeutics
  • Patent Relief Think Tank: In-depth roundtable discussions on different patent relief mechanisms including, the EU Enforcement Directive, Arrow Declaration and Cross Boarder Relief Strategies.

For the full program agenda and speakers list, download the conference brochure here: https://www.c5-online.com/pharma-biotech-patent-litigation/request-brochure/

Registration is now open. Visit the event page here: https://www.c5-online.com/pharma-biotech-patent-litigation/ for details.

Share

Warning & Disclaimer: The pages, articles and comments on IPWatchdog.com do not constitute legal advice, nor do they create any attorney-client relationship. The articles published express the personal opinion and views of the author as of the time of publication and should not be attributed to the author’s employer, clients or the sponsors of IPWatchdog.com.

Join the Discussion

No comments yet.